<DOC>
	<DOCNO>NCT02611466</DOCNO>
	<brief_summary>The purpose study evaluate analgesic efficacy ASP7962 relative placebo . This study also evaluate efficacy ASP7962 relative placebo pain walking , function stiffness ; time course efficacy ASP7962 relative placebo ; improvement overall patient status ASP7962 relative placebo well safety tolerability ASP7962 relative placebo .</brief_summary>
	<brief_title>A Study Assess Analgesic Efficacy ASP7962 Patients With Pain Due Osteoarthritis Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Patient primary diagnosis OA index knee symptom least 6 month prior screen patient meet American College Rheumatology clinical classification criterion OA knee , define follow : Knee pain least 3 follow 6 : 1 . Age &gt; 50 year 2 . Morning stiffness &lt; 30 minute 3 . Crepitus active motion 4 . Bony tenderness 5 . Bony enlargement 6 . No palpable warmth synovium Patient radiographic image index knee ( accord minimum quality criterion radiographic image set central radiology reader ) show evidence OA KellgrenLawrence grade ≥2 screen ( base central reading ) . Patient moderate severe index knee pain ( pain due OA knee least 5 day per week last 3 month prior screen , determine patient 's medical history ) . Patient ambulatory index knee must contain orthopedic and/or prosthetic device . WOMAC pain subscale score ( 48hour recall period ) index knee ≥ 4 baseline ( visit 2 predose , mean question pain subscale ) . WOMAC physical function subscale score ≥ 4 baseline ( visit 2 predose , mean question physical function subscale 48hour recall period ) . Patient willing discontinue current pain medication baseline treatment period ( day 57 ) ( except allow rescue medication ) . Low dose aspirin cardioprophylaxis allow . Patient compliant daily pain recording . Compliance diary completion define daily average pain rating least 5 day baseline period , least 3 day last 4 day prior visit 2 . Male patient female spouse/partners childbearing potential must use barrier method 1 form highly effective birth control start screen continue throughout study period 90 day final study drug administration . Male patient must donate sperm start screen throughout study period 90 day final study drug administration . Female patient must either : Be nonchildbearing potential : postmenopausal ( define least 1 year without menses ) prior screen , document surgically sterile Or , childbearing potential : agree try become pregnant study 28 day final study drug administration , negative pregnancy test screen baseline ( visit 2 predose ) , heterosexually active , agree consistently use barrier method 1 form highly effective birth control start screen continue throughout study period 28 day final study drug administration . Female patient must agree breastfeed start screen continue throughout study period 28 day final study drug administration . Female patient must donate ovum start screen continue throughout study period 28 day final study drug administration . Patient agree participate another investigational study screen followup period ( day 57 ) . Medical History / Clinical Status : Patient history suicide attempt suicidal behavior . Suicidal ideation within last 12 month ( response `` yes '' question 4 5 suicidal ideation portion ColumbiaSuicide Severity Rating Scale [ CSSRS ] ) , significant risk commit suicide , judge investigator screen time randomization . Patient current prior psychosis , major depressive disorder clinically significant psychiatric disorder . Patient current prior clinically significant neurologic disease , include limited peripheral neuropathy , stroke , cognitive impairment seizure . Childhood febrile seizure exclusionary . Patient clinically significant uncontrolled musculoskeletal disorder ( exception OA ) , cardiovascular , gastrointestinal , endocrinologic ( diabetes mellitus allow control [ glycated hemoglobin ( HbA1c ) ≤ 8.0 % ] peripheral neuropathy ) , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , dermatologic , renal and/or major disease . Patient active malignancy history malignancy ( except treat nonmelanoma skin cancer ) within past 5 year . Patient history inflammatory arthritis , ( include rheumatoid arthritis history RPOA , osteonecrosis avascular necrosis bone and/or joint ) , diagnose may increase risk RPOA ( e.g. , preexist atrophic OA , subchondral insufficiency fracture ) , severe knee malalignment jointrelated condition make patient unsuitable study participation ( e.g. , joint pain disproportionately severe , atypical feature OA pain , trigger medical evaluation rule subchondral insufficiency fracture ) . Patient finding suggestive RPOA increase risk RPOA screen radiograph either index nonindex joint ( base central reading ) . Patient history shoulder surgery , clinically significant trauma current symptom , include pain impaired range motion shoulder joint . Patient coagulopathy , receive anticoagulant diagnose thrombocytopenia functional platelet disorder . Patient history paracetamol intolerance , existence medical condition use concomitant medication paracetamol contraindicate . Patient contraindication naproxen include limited : Known hypersensitivity tramadol ( patient intolerance hypersensitivity allow , patient accepts limit rescue medication toparacetamol ) . Asthma , rhinitis , nasal polyp , urticarial allergictype reaction take aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) . Anticipated coronary artery bypass graft surgery study . Active history peptic ulceration . Active history gastrointestinal bleeding ( exception hemorrhoid ) perforation . Patient contraindication tramadol include limited Known hypersensitivity tramadol . Patient use monoamine oxidase inhibitor within 2 week prior screen screen baseline period . Patient body mass index ( BMI ) &gt; 39 kg/m2 . Cardiovascular : Patient clinically significant abnormality 12lead electrocardiogram ( ECG ) screen baseline ( visit 2 predose ) . Patient following : Lifetime history ischemic hemorrhagic stroke , cardiac arrest , torsade de pointes , clinically significant structural heart disease personal family history long QT syndrome . Within 12 month prior visit 2 : acute coronary syndrome ( e.g. , myocardial infarction , unstable angina [ ischemic heart disease allow ] ) ; transient ischemic attack ; coronary peripheral revascularization procedure ; clinically significant cardiac arrhythmia ( include atrial fibrillation flutter ) , heart block ( first degree heart block allow provide PR interval great 240 msec ) clinically significant cardiovascular disorder . Current heart failure ( New York Heart Association [ NYHA ] class III IV ) . Patient rest pulse rate &lt; 50 &gt; 100 beat per minute ( bpm ) ; systolic blood pressure ( SBP ) &gt; 160 mm Hg ; diastolic blood pressure ( DBP ) &gt; 90 mm Hg screen baseline ( visit 2 predose ) . These assessment may repeat , reasonable time period investigator 's discretion . If repeat measurement meeting criterion , patient exclude . Patient history unexplained syncopal event symptomatic orthostatic hypotension screen baseline ( visit 2 predose ) , define postural related symptom least one following : stand SBP ≥ 20 mm Hg low supine SBP , stand DBP ≥ 10 mm Hg low supine DBP . Clinical Chemistry / Hematology : Patient ( accord investigator ) clinically significant abnormality clinical chemistry , hematology urinalysis screening . These assessment may repeat , reasonable time period investigator 's discretion ( within screen period ) . Patient liver test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , total bilirubin [ TBL ] ) &gt; 1.5 time upper limit normal [ ULN ] screen . These assessment may repeat , reasonable time period investigator 's discretion ( within screen period ) . Patient estimate glomerular filtration rate ≤ 60 mL/min/1.73m2 ( Modification Diet Renal Disease [ MDRD ] calculation ) screening . Patient positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis A virus antibody ( immunoglobulin M ) ( antiHAV [ IgM ] ) , hepatitis C virus antibody ( antiHCV ) , antibodies human immunodeficiency virus type 1 ( HIV1 ) and/or type 2 ( HIV2 ) screening . Prior Medication / Medical Intervention : Patient receive investigational drug within 28 day ( 5 halflives investigational drug , whichever long ) screen schedule receive investigational drug blind study treatment course study . Patient previously receive antibody NGF within 3 month prior screen . Patient major surgery orthopedic surgery within 3 month screen plan surgical intervention study . Patient suitable candidate joint replacement surgery unable stop chronic NSAID use . Patient receive intraarticular corticosteroid intraarticular local anesthetic within 3 month prior screen , intraarticular hyaluronic acid within 6 month prior screen therapy screen baseline period . Patient receive systemic corticosteroid within past 30 day screen screen baseline period ( topical , nasal inhaled corticosteroid permit . ) Patient receive medication nonmedication therapy efficacy reduce pain OA knee , include overthecounter ( OTC ) product ( exception ice pack , rest , paracetamol ) baseline period . Patient start stop physiotherapy , acupuncture transcutaneous electrical nerve stimulation relate treatment index knee within 4 week prior screen screen baseline period . Stable regimens therapy introduce 4 week prior screen allow regimen continue unchanged study . Patient use opioids 4 day week precede screen screening period ; receive opioids baseline period . Patient use dipeptidyl peptidase 4 ( DPP4 ) inhibitor within 12 month prior visit 2 . Patient regularly use strong systemic inducer cytochrome P450 ( CYP ) 3A metabolism ( e.g. , rifampin , St John 's wort ) 3 month visit 2 . Patient comply requirement restrict prohibited medication nonmedication therapy baseline period . Recreational Drug Use : Patient positive drug screen alcohol recreational drug ( include cannabinoids ) nonprescribed controlled substance screen ( assessment may repeat , reasonable time period investigator 's discretion , within screen period ) baseline . Patient history alcohol drug abuse/dependence/misuse within 1 year prior screen . General : Patient painful condition syndrome ( e.g. , neuropathy , fibromyalgia ) concurrent medical arthritic condition potential confound assessment pain index knee , investigator 's opinion . Patient Hospital Anxiety Depression Scale ( HADS ) score &gt; 12 either subscale screening baseline ( visit 2 predose ) . Patient involve ongoing settled worker compensation claim , disability litigation relate index knee pain problem . Any condition , investigator 's opinion , make patient unsuitable study participation . Patient employee Astellas Group , Contract Research Organization ( CRO ) involve investigator site execute study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>ASP7962</keyword>
</DOC>